Literature DB >> 6116600

Specificity of a serum peptidase hydrolyzing thyroliberin at pyroglutamyl-histidine bone.

K Bauer, P Nowak, H Kleinkauf.   

Abstract

The substrate specificity of a serum enzyme which degrades thyroliberin (less than Glu-His-Pro-NH2) into pyroglutamic acid and His-Pro-NH2 has been investigated and compared with that of the pyroglutamyl aminopeptidase from calf liver. The latter enzyme has a broad specificity, causing rapid degradation of thyroliberin, pyroglutamyl beta-naphthylamide and luliberin. In contrast, the serum enzyme causes rapid stereospecific cleavage only of the pyroglutamyl-histidine bond of thyroliberin and closely related peptides. Compounds such as less than Glu-Ala, less than Glu-His and pyroglutamyl beta-naphthylamide, which are known substrates of the pyroglutamyl aminopeptidases (such as the liver enzyme), are not substrates of the serum enzyme, and inhibit it only poorly. Pyroglutamyl-containing peptides such as luliberin and neurotensin and thyroliberin analogues such as LLD-thyroliberin, less than Glu-His-Pro-NHCH3, less than Glu-His-Pro-Gly-NH2 and less than Glu-Phe-Pro-NH2 inhibit effectively the degradation of thyroliberin by the serum enzyme, but are not hydrolyzed by this enzyme. The high specificity of the serum enzyme implies a physiological function.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116600     DOI: 10.1111/j.1432-1033.1981.tb05501.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

1.  Peptide modification by incorporation ofα-trifluoromethyl substituted amino acids.

Authors:  B Koksch; N Sewald; K Burger; H D Jakubke
Journal:  Amino Acids       Date:  1996-09       Impact factor: 3.520

2.  Kinetics and pattern of degradation of thyrotropin-releasing hormone (TRH) in human plasma.

Authors:  J Møss; H Bundgaard
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

3.  Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme.

Authors:  H Bundgaard; J Møss
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

Review 4.  Neuroregulation of ProTRH biosynthesis and processing.

Authors:  E A Nillni
Journal:  Endocrine       Date:  1999-06       Impact factor: 3.633

5.  Identification of the thyrotropin-releasing-hormone-degrading ectoenzyme as a metallopeptidase.

Authors:  G Czekay; K Bauer
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

6.  Cloning of a cDNA encoding an ectoenzyme that degrades thyrotropin-releasing hormone.

Authors:  B Schauder; L Schomburg; J Köhrle; K Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

Review 7.  The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?

Authors:  Jean-Louis Charli; Adair Rodríguez-Rodríguez; Karina Hernández-Ortega; Antonieta Cote-Vélez; Rosa María Uribe; Lorraine Jaimes-Hoy; Patricia Joseph-Bravo
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

8.  Analysis of the thyrotropin-releasing hormone-degrading ectoenzyme by site-directed mutagenesis of cysteine residues. Cys68 is involved in disulfide-linked dimerization.

Authors:  T Papadopoulos; H Heuer; K Bauer
Journal:  Eur J Biochem       Date:  2000-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.